1. Home
  2. FABC vs COCP Comparison

FABC vs COCP Comparison

Compare FABC & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabric.AI Inc. Common Stock

FABC

Fabric.AI Inc. Common Stock

N/A

Current Price

$2.43

Market Cap

19.9M

ML Signal

N/A

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.24

Market Cap

21.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FABC
COCP
Founded
N/A
2006
Country
United States
United States
Employees
108
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.9M
21.6M
IPO Year
1999
2011

Fundamental Metrics

Financial Performance
Metric
FABC
COCP
Price
$2.43
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
164.8K
52.9K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
$4,579,745.00
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$0.76
52 Week High
$4.57
$2.03

Technical Indicators

Market Signals
Indicator
FABC
COCP
Relative Strength Index (RSI) 39.22 64.59
Support Level N/A $1.17
Resistance Level $2.98 $1.59
Average True Range (ATR) 0.17 0.07
MACD -0.03 0.01
Stochastic Oscillator 11.82 68.47

Price Performance

Historical Comparison
FABC
COCP

About FABC Fabric.AI Inc. Common Stock

Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: